linjc16/ctgov huggingface dataset:
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

Study Overview
=================
Brief Summary
-----------------
This placebo-controlled, double-blind, randomized pilot clinical trial will evaluate atomoxetine (Strattera®) for the treatment of cocaine dependence. Cocaine-dependent individuals, who are healthy and are seeking treatment for their substance abuse, will be randomized to receive either atomoxetine (n=25) or a matched-placebo (n=25) during a trial lasting 12 weeks; there will be a double-blind, ascending dose lead-in order to achieve maintenance on the assigned active dose safely. Contingency management procedures will be used to reinforce attendance and compliance with study procedures. Primary outcome measures will include urinalysis data assessing cocaine use.

Official Title
-----------------
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

Conditions
-----------------
Substance Abuse

Intervention / Treatment
-----------------
* Drug: atomoxetine
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Seeking treatment for cocaine dependence Must have used cocaine in the past 30 days Exclusion Criteria: Physical dependence on any drug requiring medical management Any major medical or psychiatric disorder that would be contraindicated for participation Cardiovascular disease Seizures or significant head injuries Currently taking atomoxetine Pregnant or breast-feeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Atomoxetine | Drug: atomoxetine<br>* Once daily oral dosing<br>* Other names: Straterra;|
| Placebo Comparator: 2<br>Matched Placebo | Drug: placebo<br>* Once daily oral dosing - matched placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| % Urine Samples Negative for Cocaine | Total % urine samples negative for benzoylecgonine over the 12-week trial | Urines were collected 3 times per week (e.g., Monday, Wednesday and Friday) for 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retention | Trial retention- those who complete the 12 week dosing period | 12-weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cocaine, dependence, stimulants
Adductor Canal Block in Outpatient Clinic for Pain Control After Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
Single-shot Adductor Canal Block in the outpatient clinic is safe, significantly decreased pain and analgesic consumption and may enhance the rehabilitation program

Detailed Description
-----------------
The ACB in the outpatient clinic is safe and can minimize postoperative pain. The primary goal of this research was to see how ACB affected the Visual Analog Score (VAS) pain score during the rehabilitation as opposed to controls. The secondary goal was to determine how much analgesic (etoricoxibe) was consumed on a daily basis.

Official Title
-----------------
Adductor Canal Block in Outpatient Clinic

Conditions
-----------------
Acute Pain, Total Knee Arthroplasty

Intervention / Treatment
-----------------
* Procedure: adductor canal block in outpatient clinic
* Drug: Analgesics, etoricoxibe


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indonesian or Javanese-speaking adults After perfomed total knee replacement American Society of Anesthesiologists physical status I-III body mass index (BMI) of 18-40 kg/m2 Exclusion Criteria: Declined to complete the study Unable to cooperate had an allergic reaction to any of the drugs abusing alcohol or drugs

Ages Eligible for Study
-----------------
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: pain management post total knee arthroplasty with analgetic oral<br>Patients in control group were given analgesic (etoricoxibe) on a daily basis, with the option to increase the dose if pain persisted, up to a maximum of 120 mg per day. | Drug: Analgesics, etoricoxibe<br>* anaelgetic oral intake<br>* Other names: etoricoxibe;|
| Active Comparator: pain management post total knee arthroplasty with adductor canal block<br>On postoperative day 14 (POD 14), the ACB was performed for ACB group | Procedure: adductor canal block in outpatient clinic<br>* perform adductor canal block in outpatient clinic for patient post total knee arthroplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analog pain score (VAS) | A VAS scale was used to assess pain severity, with 0 indicating no pain and 10 indicating extreme pain | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| analgesic oral intake (etoricoxibe) | determine how much analgesic (etoricoxibe) was consumed on a daily basis. | one month |
PASCAL Trabeculoplasty

Study Overview
=================
Brief Summary
-----------------
Argon laser trabeculoplasty (ALT) with 100 ms pulses is an effective therapy for lowering intraocular pressure (IOP). Similar reductions in IOP have been achieved using ns (SLT) and microsecond (MLT) pulses, which produce less thermal damage to trabecular meshwork (TM). Lack of clinically visible changes may make the accurate alignment of subsequent pulses difficult. We describe a novel technique - Patterned Laser Trabeculoplasty (PLT) using the PASCAL Photocoagulator system, and its preliminary evaluation in patients with open angle glaucoma.

Official Title
-----------------
Semi-Automated Patterned Laser Trabeculoplasty

Conditions
-----------------
Open-Angle Glaucoma

Intervention / Treatment
-----------------
* Procedure: Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-year-old patients Uncontrolled Open angle (Shaffer IV) No previous surgical trabeculoplasty or glaucoma surgery Exclusion Criteria: Patients not willing to participate Angle-closure glaucoma No clear optical media

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group 1<br>Patients with open-angle glaucoma | Procedure: Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)<br>* Pattern Scan Laser trabeculoplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular Pressure |  | During follow-up |
Effect of Electrostimulation in Chronic Obstructive Pulmonary Disease (COPD)

Study Overview
=================
Brief Summary
-----------------
This study was designed to test the following hypothesis: To investigate whether COPD muscles can respond to stimuli in terms of changes in fiber-type distribution.

Detailed Description
-----------------
Background: Muscle dysfunction is a major problem in chronic obstructive pulmonary disease (COPD). It is characterized by muscle fiber-type redistribution and oxidative stress. Classical training does not improve these features. Objectives: To investigate whether electrostimulation program following exacerbation can modify muscle structure and function in COPD patients. Method: We propose to conduct a controlled and randomized clinical trial comparing the efficacy of muscle electrostimulation training of the lower limbs to sham training in 15 patients with COPD. Patients are included in either 6 weeks of electrostimulation training (active treatment group) or 6 weeks of sham electrostimulation. Primary outcomes were changes in muscle structure, muscle oxidative stress and their relationship with quadriceps force and exercise tolerance.

Official Title
-----------------
Effect of Electromyostimulation in Severe Chronic Obstructive Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Device: Electrostimulation
* Device: Sham stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COPD patients during or after exacerbation Exclusion Criteria: Comorbidities that could limit exercise training Obesity (body mass index [BMI] > 30 kg/m²) Neuromuscular disease Pacemaker implantation

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Electrostimulation<br>Neuromuscular electrical stimulation | Device: Electrostimulation<br>* Electrostimulation: 35 Hz, 0.4 ms, 1 h; 5 times/week<br>* Other names: NMES;|
| Sham Comparator: Sham stimulation<br>Sham stimulation | Device: Sham stimulation<br>* Sham stimulation: 1 h; 5 times/week<br>* Other names: Sham;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fiber-type distribution | Typology was evaluated by immunohistochemistry | 6 to 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the strength of the quadriceps over the 6-week electrostimulation program |  | 6 to 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD
Trauma Registration at St. Olavs Hospital 2000-2003

Study Overview
=================
Brief Summary
-----------------
St. Olavs Hospital is a trauma referral center in the region of Midtnorge. Admitting trauma patients locally and those referred from hospitals in Nord-Trøndelag, Sør-Trøndelag and Møre-Romsdal.An active trauma team was defined in 1992, but it's work has not been evaluated earlier. Prospective studies of these patients were established 1st of January 2004 at St. Olavs Hospital.

Detailed Description
-----------------
This mapping is a observational retrospective study of trauma patients admitted to St.Olavs Hospital from 2000 until 2003. Patient journals (electronic and paper), autopsy reports and the emergency medical respons systems (AMK) database have been reviwed. We are reviewing the local traumaepidemiology, traumateam performance, mechanisms of injury and the potenially avoidable deaths in trauma.

Official Title
-----------------
Mapping of Traumatized Patients Referred to St. Olavs Hospital in the Period 2000-2003-Norwegian University of Science and Technology

Conditions
-----------------
Injuries, Multiple, Norway/Epidemiology, Trauma Centers/Statistics & Numerical Data, Trauma, Multiple, Trauma Severity Indices

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Trauma team activation Motor vehicle crash with ejection Pedal cyclist, motorcyclist or pedestrian hit by vehicle >30 km/h Fall > 5 meters Fatality in same vehicle Interhospital trauma transfer within 24 hrs Injury to two or more body regions Fracture to two or more long bones Spinal cord injury Amputation of a limb Penetrating injury to head, neck, torso or proximal limb Exclusion Criteria: Burns Strangulations
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adult, Child, Hospitalization/statistics & numerical data, Retrospective studies
Can Quantitative Ultrasound be Used for the Evaluation of Bone Health in Adolescents and Adults With Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
Measurement of bone density of Cystic Fibrosis patients with two techniques and correlation to serum bone parameters, use of steroids, lung function and nutritional status.

Detailed Description
-----------------
Measurement of bone density of Cystic Fibrosis patients with two techniques and correlation to serum bone parameters, use of steroids, lung function and nutritional status.

Official Title
-----------------
Can Quantitative Ultrasound be Used for the Evaluation of Bone Health in Adolescents and Adults With Cystic Fibrosis

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Procedure: Determination of bot density of Cystic Fibrosis patients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Cystic Fibrosis Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Circulating Biomarkers and Ventricular Tachyarrhythmia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether levels of inflammatory markers in circulating blood can correlate with risk for dangerous heart rhythms. Patients with systolic heart failure, which has been shown to increase risk for dangerous heart rhythms, will be enrolled. All subjects will have an implantable cardioverter-defibrillator (ICD) in place, which allows regular evaluation of heart rhythm.

Detailed Description
-----------------
If you agree to be in this study, you will be asked to the following things: you will come into the EP device clinic every three months for one year to have your device interrogated and will complete an EKG you will have labs drawn to measure levels of certain markers of inflammation in the body. This information will be used to identify new ways to test for risk of abnormal heart rhythms and other heart disease you will review your medications with the study coordinator and along with any recent illnesses or hospitalizations

Official Title
-----------------
Circulating Biomarkers and Ventricular Tachyarrhythmia

Conditions
-----------------
Cardiomyopathy, Ventricular Tachycardia, Ventricular Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: left ventricular ejection fraction [LVEF] <=35% ICD implant Exclusion Criteria: Recent myocardial infarction (12 weeks) Recent revascularization (12 weeks) Recent hospitalization for any cause (6 weeks) History of rheumatologic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to evaluate a large population of heart failure patients with regard to circulating biomarkers and rates of subsequent ventricular arrhythmias. |  | 1 year |
Acoustic Cardiographic Assessment of Heart Function and the Role of Phrenic Nerve Stimulation

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators sought to determine whether a stimulation of the phrenic nerve affects heart function. Heart function is assessed by acoustic cardiography.

Detailed Description
-----------------
Patients who need temporary pacing following open heart surgery and who are willing to participate receive a phrenic nerve electrode during the operation. Heart function is postoperatively assessed by acoustic cardiography (Audicor, Inovise Medical Inc., Portland, USA) during different forms of pacing (right ventricle, left ventricle, biventricular; AAI, DDD) and with or without phrenic nerve stimulation. Acoustic cardiography simultaneously integrates heart sounds and single-channel electrocardiography input to generate multiple parameters that correlate to established hemodynamic measures. Effects of phrenic nerve stimulation on heart function will be analyzed.

Official Title
-----------------
Acoustic Cardiographic Assessment of Heart Function and the Role of Phrenic Nerve Stimulation Following Open Heart Surgery

Conditions
-----------------
Heart Failure, Congestive, Cardiac Pacing, Artificial, Transcutaneous Electric Nerve Stimulation

Intervention / Treatment
-----------------
* Procedure: Phrenic nerve stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients following open heart surgery who need temporary pacing Exclusion Criteria: Patients with permanent pacemakers Patients with fast changing need of vasopressor therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of electrical mechanical activation time (EMAT) as measure of heart function on different settings of pacing |  | One day |
Evaluation of Lotrafilcon A Lenses Over a Three Month Period

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to assess the performance of a Lotrafilcon A contact lens over a 3-month period.

Official Title
-----------------
Evaluation of Lotrafilcon A Lenses Over a Three Month Period

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Device: Lotrafilcon A contact lens


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: On examination, have ocular findings considered to be normal and which would not prevent a subject from safely wearing contact lenses. Be willing and able to follow instructions and meet the schedule of follow-up visits as defined in the informed consent. Be able to wear the study lenses in the available powers. Currently wear contact lenses for a minimum of 5 days a week, and at least 8 hours a day. Other protocol inclusion/exclusion criteria may apply. Exclusion Criteria: Eye injury or surgery within twelve weeks immediately prior to enrollment for this trial. Pre-existing ocular irritation that would preclude contact lens fitting. Currently enrolled in an ophthalmic clinical trial. Evidence of systemic or ocular abnormality, infection or disease likely to affect successful wear of contact lenses or use of their accessory solutions. Any use of medications for which contact lens wear would be contraindicated, in the opinion of the investigator. History of corneal refractive surgery. Other protocol inclusion/exclusion criteria may apply.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lotrafilcon A<br> | Device: Lotrafilcon A contact lens<br>* Silicone hydrogel, spherical, soft contact lens<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comfort After Insertion | Comfort after insertion of contact lens (30 seconds to 1 minute), as interpreted by the subject and reported by the subject as a single, retrospective evaluation of 3-month's wear time. Comfort after insertion was measured on a 10-point scale, with 1 being poor and 10 being excellent. | 3 months |